KURA vs SNDX
KURA: A clinical-stage oncology biopharmaceutical company developing targeted, small-molecule precision therapies for cancer patients. SNDX: A clinical-stage biopharmaceutical company developing targeted, small-molecule therapies to treat cancer and chronic graft-versus-host disease.
Side-by-side fundamentals
| Metric | KURA | SNDX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $10.52 | $16.90 | |
| Market cap | $936M | $1.5B | |
| Net margin FY2025, SEC XBRL | -412.9% | -165.6% | SNDX higher |
| Operating margin FY2025, SEC XBRL | -449.9% | -158.4% | SNDX higher |
| ROE FY2025, SEC XBRL | -160.0% | -441.6% | KURA higher |
| ROA FY2025, SEC XBRL | -37.7% | -53.9% | KURA higher |
| Debt / equity as of 2026-09-02 | 0.09 | 38.95 | KURA lower |
| Revenue growth (YoY) as of 2026-09-02 | +29.5% | +222.7% | SNDX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.04 | 1.04 | |
| 1-year return as of 2026-10-08 close | +4.4% | +2.4% | KURA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.